Metabolic Pathways and Cardiovascular Unit, GlaxoSmithKline, Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406, USA.
Urology. 2012 Jun;79(6):1410.e1-6. doi: 10.1016/j.urology.2012.02.016. Epub 2012 Apr 11.
To evaluate the consequence of pharmacologic inhibition of voltage-gated Na(+) channels (Nav) in the conscious rat, based on Nav having been implicated as modulators of rodent urodynamics using knockout as well as antisense oligodeoxynucleotide approaches.
The urodynamic response to standard Nav blockers, lamotrigine, amitriptyline, mexiletine, and carbamazepine were evaluated using conscious, continuous-filling cystometry in spontaneously hypertensive rats (SHRs). As a selectivity evaluation, the activity of the Nav blockers at muscarinic receptors was assessed via effect on carbachol-evoked bladder contractions.
Lamotrigine, amitriptyline, mexiletine, and carbamazepine decreased peak micturition pressure, micturition interval, and void volume. These effects were markedly similar to observations with muscarinic antagonists. Therefore, we evaluated the selectivity of these agents against bladder muscarinic receptors. Lamotrigine, mexiletine, and carbamazepine had no effect on muscarinic bladder contractions, whereas amitriptyline displayed a robust antagonism of carbachol-induced contractility.
Three Nav blockers--lamotrigine, mexiletine, and carbamazepine--demonstrated a reduction in micturition pressure and functional bladder capacity, similar to previous observations with muscarinic antagonists. These 3 Nav blockers are free of muscarinic antagonism, consistent with their cystometric effects being mediated via their Nav blocking activities. The negative findings reported here with Nav blockers suggest that Nav channel blockade is unlikely to reflect an improved treatment strategy for bladder disorders over currently prescribed muscarinic antagonists.
评估电压门控钠离子通道(Nav)药理学抑制在清醒大鼠中的后果,因为 Nav 已被证明通过敲除和反义寡核苷酸方法作为啮齿动物尿动力学调节剂。
使用清醒、连续填充膀胱测压法,在自发性高血压大鼠(SHR)中评估标准 Nav 阻滞剂拉莫三嗪、阿米替林、美西律和卡马西平的尿动力学反应。作为选择性评估,通过对卡巴胆碱诱发的膀胱收缩的影响来评估 Nav 阻滞剂在毒蕈碱受体上的活性。
拉莫三嗪、阿米替林、美西律和卡马西平降低了排尿峰值压力、排尿间隔和排空量。这些作用与毒蕈碱拮抗剂的观察结果非常相似。因此,我们评估了这些药物对膀胱毒蕈碱受体的选择性。拉莫三嗪、美西律和卡马西平对毒蕈碱诱导的膀胱收缩没有影响,而阿米替林则显示出对卡巴胆碱诱导的收缩性的强烈拮抗作用。
三种 Nav 阻滞剂——拉莫三嗪、美西律和卡马西平——显示出排尿压力和功能性膀胱容量的降低,与先前使用毒蕈碱拮抗剂的观察结果相似。这 3 种 Nav 阻滞剂没有毒蕈碱拮抗作用,与它们的膀胱测压作用通过其 Nav 阻断活性介导一致。这里报告的 Nav 阻滞剂的阴性结果表明,Nav 通道阻断不太可能反映出改善膀胱疾病治疗策略的优于目前规定的毒蕈碱拮抗剂。